Other safety alerts
|
| |
| Australia: Continuing imports of counterfeit Botox vials |
| |
The Therapeutic Goods Administration (TGA) continues to see imports of counterfeit Botox vials despite a previous warning issued in July 2025. The counterfeit products were packaged to appear as a genuine Botox branded product manufactured by Allergan, an AbbVie company. However, AbbVie has confirmed these products, with batch number C8478C4, are not genuine.
Counterfeit products have not been assessed by TGA for quality, safety or efficacy. These products pose a significant public health and safety risk and should not be used. As with the previous warning, these products were purchased online from an overseas website and not from an Australian pharmacy. Manufacturers of counterfeit goods are producing products that may appear legitimate. This highlights the importance of purchasing medicines from legitimate sources. Botulinum toxin products are prescription-only medicines in Australia. Patients seeking cosmetic injectables are at increased risk of adverse events when injected with products that have not been approved for supply in Australia.
Please refer to the following website in TGA for details:
http://www.tga.gov.au/safety/safety-monitoring-and-information/../continuing-imports-counterfeit-botox-vials
In Hong Kong, Botox For Inj 100 Units (HK-41906) is a pharmaceutical product registered by Allergan Hong Kong Limited. The product is a prescription-only medicine. The pack of the counterfeit Botox product referenced in the above TGA’s announcement is different from the registered pack of the product in Hong Kong. Related news was previously issued by TGA, and was posted on the Drug Office website on 11 Jul 2025.
Ends/Tuesday, Jan 27, 2026
Issued at HKT 18:30
|
| |
|
